HC Wainwright Cuts Nuvation Bio (NYSE:NUVB) Price Target to $17.00

Nuvation Bio (NYSE:NUVB) had its target price cut by HC Wainwright from $18.00 to $17.00 in a research note released on Monday morning, Marketbeat.com reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Nuvation Bio’s Q1 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.35) EPS.

Several other brokerages have also weighed in on NUVB. UBS Group initiated coverage on shares of Nuvation Bio in a research report on Wednesday, January 7th. They issued a “neutral” rating and a $10.00 price objective on the stock. JMP Securities set a $10.00 price target on shares of Nuvation Bio in a report on Thursday, November 20th. Jefferies Financial Group started coverage on shares of Nuvation Bio in a research report on Tuesday, September 30th. They set a “buy” rating and a $10.00 price objective for the company. B. Riley began coverage on Nuvation Bio in a research report on Wednesday, November 19th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvation Bio in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Nuvation Bio currently has an average rating of “Moderate Buy” and a consensus target price of $10.40.

Nuvation Bio Stock Performance

NUVB opened at $6.29 on Monday. The company has a quick ratio of 8.39, a current ratio of 8.48 and a debt-to-equity ratio of 0.14. Nuvation Bio has a 12-month low of $1.54 and a 12-month high of $9.75. The business has a 50 day moving average of $7.66 and a 200-day moving average of $4.72. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -9.83 and a beta of 1.54.

Nuvation Bio (NYSE:NUVB) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. Nuvation Bio had a negative return on equity of 54.99% and a negative net margin of 813.07%.The business had revenue of $13.12 million for the quarter, compared to analysts’ expectations of $7.48 million. On average, equities research analysts expect that Nuvation Bio will post -0.36 earnings per share for the current year.

Insider Activity at Nuvation Bio

In other news, insider Dongfang Liu sold 150,000 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $7.82, for a total transaction of $1,173,000.00. Following the completion of the sale, the insider directly owned 18,000 shares in the company, valued at approximately $140,760. This represents a 89.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Gary Hattersley sold 100,000 shares of the stock in a transaction on Monday, October 27th. The stock was sold at an average price of $5.02, for a total value of $502,000.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 320,000 shares of company stock valued at $2,050,800. 29.93% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Nuvation Bio

Several hedge funds have recently bought and sold shares of NUVB. Hennion & Walsh Asset Management Inc. raised its position in shares of Nuvation Bio by 31.2% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 445,279 shares of the company’s stock valued at $3,990,000 after buying an additional 106,008 shares in the last quarter. Wealthcare Advisory Partners LLC bought a new position in Nuvation Bio in the fourth quarter valued at approximately $958,000. SG Americas Securities LLC increased its stake in Nuvation Bio by 9.6% in the fourth quarter. SG Americas Securities LLC now owns 61,791 shares of the company’s stock valued at $554,000 after acquiring an additional 5,395 shares during the last quarter. JPMorgan Chase & Co. raised its position in Nuvation Bio by 472.8% during the third quarter. JPMorgan Chase & Co. now owns 675,600 shares of the company’s stock valued at $2,500,000 after purchasing an additional 557,656 shares in the last quarter. Finally, Swiss Life Asset Management Ltd bought a new stake in Nuvation Bio during the third quarter worth $39,000. 61.67% of the stock is owned by institutional investors.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.